# Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas

> facility in Madrid, Spain

**Wikidata**: [Q30281642](https://www.wikidata.org/wiki/Q30281642)  
**Source**: https://4ort.xyz/entity/centro-de-investigacion-biomedica-en-red-sobre-enfermedades-neurodegenerativas

## Summary
The Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) is a specialized biomedical research institute in Madrid, Spain, established in 2008 to investigate neurodegenerative diseases. As part of the CIBER network, it operates as a dedicated research organization, focusing on advancing knowledge in neuroscience and related fields through systematic investigation.

## Key Facts
- **Founded**: 2008
- **Location**: Madrid, Spain
- **Coordinates**: 40.373279° N, 3.627378° W
- **Website**: http://www.ciberned.es/ (available in multiple languages)
- **Aliases**: CIBERNED
- **Instance Of**: Facility, research institute, organization
- **GRID ID**: grid.418264.d
- **Ringgold ID**: 145219
- **EU VAT Number**: ESG84905439
- **EU Participant Identification Code**: 998071510
- **Country**: Spain

## FAQs
### Q: When was CIBERNED established?
A: CIBERNED was founded in 2008 as part of Spain’s network of biomedical research centers (CIBER), focusing on neurodegenerative diseases.

### Q: What is CIBERNED’s primary focus?
A: The institute specializes in research on neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, addressing their causes, diagnosis, and treatment through multidisciplinary scientific collaboration.

### Q: How is CIBERNED structured?
A: As a research institute, CIBERNED operates independently of university teaching obligations, concentrating solely on investigative work. It collaborates with other institutions within the CIBER network to pool resources and expertise.

### Q: What distinguishes CIBERNED from general research institutes?
A: Unlike broader research institutes, CIBERNED is narrowly focused on neurodegenerative diseases, integrating clinical, translational, and basic research for targeted medical advancements.

## Why It Matters
CIBERNED plays a critical role in addressing the global challenge of neurodegenerative diseases, which affect millions worldwide. By consolidating expertise and resources in Madrid, the institute accelerates the discovery of diagnostic tools, therapies, and preventive strategies. Its work directly contributes to improving patient outcomes and reducing healthcare burdens, positioning Spain as a leader in neuroscience research. As part of the CIBER network, CIBERNED fosters national and international collaboration, ensuring findings translate into clinical practice and policy, ultimately enhancing quality of life for affected individuals and their families.

## Notable For
- **Specialized Focus**: Exclusive dedication to neurodegenerative disease research, differentiating it from general medical research institutes.
- **CIBER Network Affiliation**: Part of Spain’s national biomedical research consortium (CIBER), enabling resource sharing and strategic collaboration.
- **Multidisciplinary Approach**: Combines clinical, biological, and technological research for comprehensive insights into complex neurological conditions.
- **Unique Identifiers**: Recognized by distinct codes (e.g., GRID ID, Ringgold ID, EU VAT number), ensuring precise attribution in scientific literature and funding frameworks.

## Body
### Founding and Structure
CIBERNED was established in 2008 as a key component of Spain’s Centro de Investigación Biomédica en Red (CIBER) initiative, a national program to bolster biomedical research. Headquartered in Madrid, it operates as an autonomous research institute, unaffiliated with university teaching duties, allowing concentrated effort on investigative work. Its structure emphasizes collaboration, linking clinicians, biologists, and technologists across Spain to tackle neurodegenerative diseases.

### Research Focus
The institute prioritizes translational research, bridging laboratory discoveries with clinical applications. Key areas include molecular mechanisms of neurodegeneration, biomarker identification, and therapeutic development. By focusing on conditions like Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS), CIBERNED addresses high-prevalence diseases with significant societal impact. Its work spans genetic studies, neuroimaging, and drug trials, reflecting a commitment to both basic science and patient-centered outcomes.

### Organizational Identity
As a registered facility (GRID ID: grid.418264.d), CIBERNED is classified under international organizational taxonomies, including schema.org/ResearchOrganization. Its Ringgold ID (145219) and EU VAT number (ESG84905439) facilitate administrative and financial interactions within European research frameworks. The institute’s participation in the CIBER network amplifies its reach, aligning with national health priorities while maintaining agility as a standalone entity.

### Geographic and Digital Presence
Based in Madrid, CIBERNED benefits from proximity to major Spanish healthcare and academic institutions, fostering partnerships and talent recruitment. Its coordinates (40.373279° N, 3.627378° W) place it within a hub of scientific activity. The institute’s website (http://www.ciberned.es/) serves as a multilingual platform for disseminating research, promoting public engagement, and connecting with global stakeholders.

### Classifications and Identifiers
CIBERNED is formally recognized through multiple identifiers:
- **GRID ID**: grid.418264.d (Global Research Identifier Database)
- **Ringgold ID**: 145219 (institutional identifier for academic and healthcare organizations)
- **EU Participant ID**: 998071510 (for EU-funded research projects)
- **ISNI**: 0000000417624012 (International Standard Name Identifier)

These designations ensure precise attribution in publications, grants, and collaborative projects, enhancing the institute’s visibility in global research ecosystems.

### Legacy and Impact
Since its inception, CIBERNED has contributed to advancements in neurodegenerative disease research, including studies on early diagnosis and personalized medicine. Its integration of clinical and experimental approaches models effective translational research, influencing both scientific methodologies and healthcare policy. By addressing diseases with rising prevalence in aging populations, the institute supports sustainable healthcare systems and aligns with international efforts to mitigate the social and economic consequences of neurodegeneration.

## References

1. GRID Release 2017-05-22
2. Aligned ISNI and Ringgold identifiers for institutions